Early use of low-dose hydrocortisone can reduce in-hospital mortality in patients with septic shock: A systematic review and meta-analysis

Binglin Song,Xiangde Zheng,Kangrui Fu,Chun Liu

DOI: https://doi.org/10.1097/md.0000000000040635

IF: 1.6

2024-12-01

Medicine

Abstract:Based on literature data, the estimated global fatality rate for severely ill patients with septic shock is around 40%. [ 1–3 ] The current approach to treating septic Huk involves promptly administering fluids, using vasoactive medications, and prescribing antibiotics. Nevertheless, the extended utilization of vasoactive medications can result in a lengthened duration of hospitalization and heightened death rates. [ 3–6 ] The Exercise Guidelines for Surviving Sepsis suggest using HC adjuvant therapy for individuals with severe symptoms who need a norepinephrine dose of 0.25 mg/kg/min or higher for more than 4 hours. [ 6 ] The utilization of glucocorticoids in individuals experiencing septic shock may be traced back to the 1950s. The initial modest randomized controlled studies conducted by Hahn, Weitzman, and other researchers yielded contradictory outcomes. [ 7 , 8 ] In 1987, Bone et al showed that administering high dosages of glucocorticoids to patients with severe sepsis and septic shock could lead to an elevated rate of mortality during their hospital stay. [ 9 , 10 ] In 2002, Annane et al conducted a research which demonstrated that a 7-day regimen of low-dose hydrocortisone (HC) was effective in decreasing mortality rates. [ 11 ] In 2004, the Surviving Sepsis Campaign (SSC) guideline provided recommendations for the administration of glucocorticoids for patients diagnosed with septic shock. [ 12 ] In the studies of Sprung et al [ 13 ] and Annane et al, [ 11 ] 2 Sebille trials demonstrated that the use of hydrocortisone (HC) did not result in a decrease in the death rate of patients with septic shock. [ 11 , 13 ] As a result, the guidelines from the SSC were modified from a "recommended" status in 2004 to a continued "recommended" status in 2008. In 2011, Annane, D. conducted a study along with Renault, A. et al which shown that HC-assisted treatment of sepsis resulted in a reduction in 90-day mortality to 43% compared to 49%. [ 14 ] In 2010, Fang, F. also conducted a related study. A recent small-scale randomized controlled trial (COIITSS) conducted by et al demonstrated that the use of HC may lead to a decrease in 28-day mortality. [ 15 , 16 ] Consequently, the 2021 SSC guidelines have updated their recommendation about the use of HC in patients with septic shock, now considering it a weak recommendation. [ 2 ] A meta-analysis conducted in May 2023 examined the effects of low-dose hydrocortisone (HC) on persons with septic shock. The investigation found that HC may lead to an increased risk of mortality, with a relative risk (RR) of 0.86 for 90-day mortality. [ 17 ] Based on many research, our analysis determined that the use of low-dose hydrocortisone (HC) as an additional treatment may decrease the likelihood of death during a hospital stay for patients with septic shock. However, there is no specific information available regarding when to start HC therapy. We performed a meta-analysis by gathering data from published randomized controlled trials (RCTs) and cohort studies to evaluate the effects of starting low-doses of hydrocortisone (HC) at various time intervals on the clinical outcomes of patients with septic shock.

medicine, general & internal